GE HealthCare Technologies Inc. $GEHC Position Trimmed by Cooper Investors PTY Ltd.

Key Points

• Cooper Investors PTY Ltd. reduced its stake in GE HealthCare Technologies by 63.6%, holding 78,647 shares valued at $5,825,000 after selling 137,204 shares.
• Analysts have varied opinions on GE HealthCare, with Morgan Stanley lowering its target price from $78.00 to $74.00, while Citigroup raised its target from $89.00 to $93.00, indicating a mix of insights on the stock's future.
• GE HealthCare Technologies announced a quarterly dividend of $0.035 per share, yielding 0.2%, reflecting its ongoing commitment to returning value to shareholders.

Cooper Investors PTY Ltd. trimmed its position in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC - Free Report) by 63.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 78,647 shares of the company's stock after selling 137,204 shares during the period. Cooper Investors PTY Ltd.'s holdings in GE HealthCare Technologies were worth $5,825,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently bought and sold shares of the company. D. E. Shaw & Co. Inc. lifted its holdings in shares of GE HealthCare Technologies by 44.8% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 25,810 shares of the company's stock valued at $2,018,000 after buying an additional 7,980 shares during the last quarter. Tidal Investments LLC increased its position in GE HealthCare Technologies by 7.7% in the 4th quarter. Tidal Investments LLC now owns 25,532 shares of the company's stock worth $1,996,000 after buying an additional 1,817 shares during the period. Vident Advisory LLC lifted its holdings in shares of GE HealthCare Technologies by 14.3% during the fourth quarter. Vident Advisory LLC now owns 5,893 shares of the company's stock worth $461,000 after buying an additional 738 shares during the last quarter. Woodline Partners LP lifted its position in GE HealthCare Technologies by 30.3% in the fourth quarter. Woodline Partners LP now owns 93,387 shares of the company's stock worth $7,301,000 after purchasing an additional 21,718 shares during the period. Finally, Waverly Advisors LLC boosted its position in shares of GE HealthCare Technologies by 87.3% during the 4th quarter. Waverly Advisors LLC now owns 5,493 shares of the company's stock valued at $429,000 after acquiring an additional 2,560 shares in the last quarter. 82.06% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have weighed in on GEHC shares. Morgan Stanley cut their target price on GE HealthCare Technologies from $78.00 to $74.00 and set an "equal weight" rating on the stock in a research note on Thursday, July 31st. Zacks Research raised shares of GE HealthCare Technologies from a "hold" rating to a "strong-buy" rating in a research report on Thursday, August 28th. Citigroup lifted their price objective on shares of GE HealthCare Technologies from $89.00 to $93.00 and gave the stock a "buy" rating in a research note on Thursday, July 31st. BTIG Research reissued a "buy" rating on shares of GE HealthCare Technologies in a report on Monday, July 14th. Finally, Wall Street Zen upgraded GE HealthCare Technologies from a "hold" rating to a "buy" rating in a research report on Saturday, May 31st. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and two have issued a Hold rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $88.40.

GE HealthCare Technologies Stock Performance

Shares of GEHC opened at $74.00 on Friday. GE HealthCare Technologies Inc. has a 12 month low of $57.65 and a 12 month high of $94.80. The company has a current ratio of 1.16, a quick ratio of 0.93 and a debt-to-equity ratio of 0.85. The firm's fifty day simple moving average is $74.54 and its two-hundred day simple moving average is $73.33. The stock has a market capitalization of $33.79 billion, a P/E ratio of 15.16, a price-to-earnings-growth ratio of 2.93 and a beta of 1.13.

GE HealthCare Technologies (NASDAQ:GEHC - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The company reported $1.06 earnings per share for the quarter, topping the consensus estimate of $0.91 by $0.15. GE HealthCare Technologies had a net margin of 11.22% and a return on equity of 23.93%. The firm had revenue of $5 billion for the quarter, compared to the consensus estimate of $4.96 billion. During the same quarter in the prior year, the company posted $1.00 earnings per share. The business's revenue was up 3.5% on a year-over-year basis. GE HealthCare Technologies has set its FY 2025 guidance at 4.430-4.630 EPS. As a group, analysts predict that GE HealthCare Technologies Inc. will post 4.68 EPS for the current year.

GE HealthCare Technologies Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, August 15th. Shareholders of record on Friday, July 25th were given a dividend of $0.035 per share. This represents a $0.14 dividend on an annualized basis and a yield of 0.2%. The ex-dividend date was Friday, July 25th. GE HealthCare Technologies's dividend payout ratio (DPR) is currently 2.87%.

About GE HealthCare Technologies

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.